Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$15.65 +4.1%	$15.14	$7.08 ▼ $17.49	$324.06M	0.84	66,372 shs	81,433 shs
BNTC Benitec Biopharma	$13.01 +2.8%	$12.93	$8.06 ▼ $17.15	$341.51M	0.4	53,404 shs	58,291 shs
CELU Celularity	$3.48 +0.6%	$2.51	$1.00 ▼ $5.22	$83.34M	0.79	180,072 shs	26,513 shs
RCKT Rocket Pharmaceuticals	$3.05 +0.7%	$2.96	$2.19 ▼ $22.01	$329.11M	0.65	2.70 million shs	1.43 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	+4.06%	+4.40%	-1.26%	+47.92%	+27.94%
BNTC Benitec Biopharma	+2.76%	+10.25%	+10.72%	-4.34%	+49.03%
CELU Celularity	+0.58%	+7.41%	+62.62%	+70.59%	+17.97%
RCKT Rocket Pharmaceuticals	+0.66%	+6.64%	+6.64%	-53.08%	-83.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.1972 of 5 stars	0.5	2.0	0.0	2.2	0.0	0.6
BNTC Benitec Biopharma	1.7438 of 5 stars	3.6	1.0	0.0	2.8	0.8	0.0
CELU Celularity	0.4263 of 5 stars	0.0	1.0	0.0	3.6	1.7	0.0
RCKT Rocket Pharmaceuticals	4.8382 of 5 stars	4.2	4.0	4.7	1.2	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.00	Sell	$12.00	-23.32% Downside
BNTC Benitec Biopharma	3.13	Buy	$26.00	99.85% Upside
CELU Celularity	0.00	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	2.35	Hold	$16.33	435.52% Upside

Current Analyst Ratings Breakdown

Latest CELU, AMRN, BNTC, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
7/25/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
7/25/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$9.00 ➝ $4.00
7/24/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $12.00
7/24/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/25/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$7.00 ➝ $12.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$228.61M	1.42	N/A	N/A	$22.45 per share	0.70
BNTC Benitec Biopharma	$80K	4,268.91	N/A	N/A	$4.68 per share	2.78
CELU Celularity	$54.22M	1.54	N/A	N/A	$0.37 per share	9.41
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$82.18M	-$3.67	N/A	N/A	N/A	-47.22%	-21.18%	-15.00%	10/29/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CELU Celularity	-$57.89M	-$2.65	N/A	∞	N/A	-106.77%	-271.88%	-42.82%	8/18/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.51	N/A	N/A	N/A	N/A	-65.11%	-55.99%	N/A

Latest CELU, AMRN, BNTC, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A
7/30/2025	Q2 2025	AMRN Amarin	-$0.66	-$0.03	+$0.63	-$0.03	$45.45 million	$72.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CELU Celularity	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.26	2.34
BNTC Benitec Biopharma	0.01	14.80	14.80
CELU Celularity	4.07	0.38	0.28
RCKT Rocket Pharmaceuticals	0.05	6.39	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
BNTC Benitec Biopharma	52.19%
CELU Celularity	19.02%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	3.30%
BNTC Benitec Biopharma	1.30%
CELU Celularity	22.10%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	20.71 million	20.02 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CELU Celularity	220	23.95 million	18.66 million	Optionable
RCKT Rocket Pharmaceuticals	240	107.90 million	81.19 million	Optionable

CELU, AMRN, BNTC, and RCKT Headlines

Recent News About These Companies

What is Chardan Capital's Forecast for RCKT FY2025 Earnings?

August 16 at 9:41 AM | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $16.40 Consensus Price Target from Analysts

August 14 at 2:07 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $11.00 at Chardan Capital

August 13 at 2:06 AM | americanbankingnews.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact Levi & Korsinsky

August 12, 2025 | theglobeandmail.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $11.00 by Analysts at Chardan Capital

August 12, 2025 | marketbeat.com

Rocket Pharmaceuticals Announces Strategic Restructuring and Leadership Changes

August 12, 2025 | theglobeandmail.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

August 12, 2025 | theglobeandmail.com

Levi & Korsinsky Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT

August 11, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

August 11, 2025 | prnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 11, 2025 | marketbeat.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm

August 11, 2025 | prnewswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Hold" from Brokerages

August 11, 2025 | marketbeat.com

RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

August 10, 2025 | prnewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 10, 2025 | globenewswire.com

RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT

August 10, 2025 | globenewswire.com

RCKT DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August ...

August 10, 2025 | barrons.com

Cantor Fitzgerald Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $8.00

August 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

August 9, 2025 | globenewswire.com

Faruqi & Faruqi Reminds Rocket Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

August 9, 2025 | prnewswire.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors – Contact Levi & Korsinsky

August 8, 2025 | globenewswire.com

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

August 8, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, AMRN, BNTC, and RCKT Company Descriptions

Amarin NASDAQ:AMRN

$15.65 +0.61 (+4.06%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$15.79 +0.14 (+0.89%)

As of 08/15/2025 06:11 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Benitec Biopharma NASDAQ:BNTC

$13.01 +0.35 (+2.76%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$12.08 -0.94 (-7.19%)

As of 08/15/2025 07:55 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Celularity NASDAQ:CELU

$3.48 +0.02 (+0.58%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.41 -0.07 (-2.01%)

As of 08/15/2025 04:10 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.05 +0.02 (+0.66%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.04 -0.01 (-0.33%)

As of 08/15/2025 07:31 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time